Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration

European Journal of Medicinal Chemistry

Volumn 45, Issue 4, 2010, Pages 1598-1617

  Abu Khalaf, Reema ^a   Abu Sheikha, Ghassan ^a   Bustanji, Yasser ^b   Taha, Mutasem O ^b  

^a AL ZAYTOONAH UNIVERSITY OF JORDAN   (Jordan)

^b UNIVERSITY OF JORDAN   (Jordan)

Author keywords

CETP inhibitors; In silico screening; Pharmacophore modeling; Quantitative Structure activity relationship; Receiver operating characteristic; Shape constraints

Indexed keywords

AGRICULTURAL CHEMICAL; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; MOLECULAR SCAFFOLD; NSC 40331; NSC 89508; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; COMPUTER MODEL; DATA BASE; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; IC 50; LIGAND BINDING; PHARMACOPHORE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STATISTICAL MODEL;

CHOLESTEROL ESTER TRANSFER PROTEINS; DRUG DISCOVERY; HYDROGEN BONDING; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; ROC CURVE;

EID: 77349098506     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2009.12.070     Document Type: Article

References (56)

1. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352 (2005) 1685-1695
2. Lamarche B., Despres J.P., Moorjani S., Cantin B., Dagenais G.R., and Lupien P.J. Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease, Results from the Quebec cardiovascular study. Atherosclerosis 119 (1996) 235-245
3. Tall A.R., Wang N., and Mucksavage P. Is it time to modify the reverse cholesterol transport model?. J. Clin. Invest 108 (2001) 1273-1275
4. Qiu X., Mistry A., Ammirati M.J., Chrunyk B.A., Clark R.W., Cong Y., Culp J.S., Danley D.E., Freeman T.B., Geoghegan K.F., Griffor M.C., Hawrylik S.J., Hayward C.M., Hensley P., Hoth L.R., Karam G.A., Lira M.E., Lloyd D.B., McGrath K.M., Stutzman-Engwall K.J., Subashi A.K., Subashi T.A., Thompson J.F., Wang I.K., Zhao H., and Seddon A.P. Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat. Struct. Mol. Biol. 14 (2007) 106-113
5. Boekholdt S.M., Kuivenhoven J.A., Wareham N.J., Peters R.J.G., Jukema J.W., Luben R., Bingham S.A., Day N.E., Kastelein J.J.P., and Khaw K.T. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women. Circulation 110 (2004) 1418-1423
6. McPherson R., Mann C.J., Tall A.R., Hogue M., Martin L., Milne R.W., and Marcel Y.L. Plasma concentration of cholesteryl ester transfer protein in hyperlipoproteinemia. Arterioscler. Thromb 11 (1991) 797-804
7. Castilho M.S., Marcelo S., Guido R.V.C., and Andricopulo A.D. 2D Quantitative structure-activity relationship studies on a series of cholesteryl ester transfer protein inhibitors. Bioorg. Med. Chem. 15 (2007) 6242-6252
8. Hanumantharao P., Sambasivarao S.V., Soni L.K., Gupta A.K., and Kaskhedikar S.G. QSAR analysis of analogs of bis[2-(acylamino) Ph] disulfides, 2-(acylamino) benzenethiols and S-[2-(acylamino) Ph] alkanethioates as antihyperlipidemic agents. Ind. J. Chem., Sect. B, Org. Chem. Includ. Med. Chem. 44B (2005) 1481-1486
9. Kelkar M.A., Pednekar D.V., Pimple S.R., and Akamanchi K.G. 3D QSAR studies of inhibitors of cholesterol ester transfer protein (CETP) by CoMFA, CoMSIA and GFA methodologies. Med. Chem. Res. 13 (2004) 590-604
10. Cronin M.T.D., and Schultz T.W. Pitfalls in QSAR. J. Mol. Struct. (Theochem.) 622 (2003) 39-51
11. Akamatsu M. Current state and perspectives of 3D-QSAR. Curr. Top. Med. Chem. 12 (2002) 1381-1394
12. Taha M.O., Bustanji Y., Al-Ghussein M., Mohammad M., Zalloum H., Al-Masri I.M., and Atallah N. Pharmacophore modeling, quantitative structure-activity relationship analysis, and in-silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin. J. Med. Chem. 51 (2008) 2062-2077
13. Al-masri I.M., Mohammad K., and Taha M.O. Discovery of DPP IV inhibitors by pharmacophore modeling and QSAR analysis followed by in silico screening. Chem. Med. Chem. 3 11 (2008) 1763-1779
14. Taha M.O., Dahabiyeh L.A., Bustanji Y., Zalloum H., and Saleh S. Combining ligand-based pharmacophore modeling, QSAR analysis and in-silico screening for the discovery of new potent hormone sensitive lipase inhibitors. J. Med. Chem. 51 (2008) 6478-6494
15. Taha M.O., Atallah N., Al-Bakri A.G., Paradis-Bleau C., Zalloum H., Younis K., and Levesque R.C. Discovery of new MurF Inhibitors via pharmacophore modeling and QSAR analysis followed by in silico screening. Bioorg. Med. Chem. 16 (2008) 1218-1235
16. Taha M.O., Bustanji Y., Al-Bakri A.G., Yousef M., Zalloum W.A., Al-Masri I.M., and Atallah N. Discovery of new potent human protein tyrosine phosphatase inhibitors via pharmacophore and QSAR analysis followed by in silico screening. J. Mol. Graphics Model 25 (2007) 870-884
17. Abu Hammad A.M., and Taha M.O. Pharmacophore modeling, quantitative structure-activity relationship analysis, and shape-complemented in silico screening allow access to novel influenza neuraminidase inhibitors. J. Chem. Inf. Model. 49 (2009) 978-996
18. Catalyst User Guide (2005), Accelrys Software Inc., San Diego, CA
19. Sprague P.W., and Hoffmann R. In: Van de Waterbeemd H., Testa B., and Folkers G. (Eds). CATALYST Pharmacophore Models and Their Utility As Queries for Searching 3D Databases, Current Tools for Medicinal Chemistry (1997), VHCA, Basel 223-240
20. Barnum D., Greene J., Smellie A., and Sprague P.J. Identification of Common Functional configurations among molecules. Chem. Inf. Comput. Sci. 36 (1996) 563-571
21. Smellie A., Teig S., and Towbin P. Poling: promoting conformational variation. J. Comput. Chem. 16 (1995) 171-187
22. Li H., Sutter J., and Hoffmann R. In: Guner O.F. (Ed). Pharmacophore Perception, Development, and Use in Drug Design (2000), International University Line, California 173-189
23. Sutter J., Guner O.F., Hoffmann R., Li H., and Waldman M. Effect of Variable Weights and Tolerances on Predictive Model Generation, Pharmacophore Perception, Development, and Use in Drug Design (2000), International University Line, California pp. 501-511
24. Kurogi Y., and Guner O.F. Pharmacophore modeling and three-dimensional database searching for drug design using catalyst. Curr. Med. Chem. 8 (2001) 1035-1055
25. Bersuker I.B., Bahçeci S., and Boggs J.E. Pharmacophore Perception, Development, and Use in Drug Design. In: Gu{combining double acute accent}ner O.F. (Ed) (2000), International University Line, California 457-473
26. Poptodorov K., Luu T., and Hoffmann R. In: Langer T., and Hoffmann R.D. (Eds). Methods and Principles in Medicinal Chemistry, Pharmacophores and Pharmacophores Searches (2006), Wiley-VCH, Weinheim 2 17-47
27. Singh J., Chuaqui C.E., Boriack-Sjodin P.A., Lee W.C., Pontz T., Corbley M.J., Cheung H.K., Arduini R.M., Mead J.N., Newman M.N., Papadatos J.L., Bowes S., Josiah S., and Ling L.E. Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFβ receptor kinase (TβRI). Bioorg. Med. Chem. Lett. 13 (2003) 4355-4359
28. Taha M.O., Qandil A.M., Zaki D.D., and AlDamen M.A. Ligand-based assessment of factor Xa binding site flexibility via elaborate pharmacophore exploration and genetic algorithm-based QSAR modeling. Eur. J. Med. Chem. 40 (2005) 701-727
29. Keller P.A., Bowman M., Dang K.H., Garner J., Leach S.P., Smith R., and McCluskey A.J. Pharmacophore development for corticotropin-releasing hormone: new insights into inhibitor activity. J. Med. Chem. 42 (1999) 2351-2357
30. Karki R.G., and Kulkarni V.M. A feature based pharmacophore for Candida albicans MyristoylCoA: protein N-myristoyltransferase inhibitors. Eur. J. Med. Chem. 36 (2001) 147-163
31. Taha M.O., Al-Bakri A.G., and Zalloum W.A. Discovery of potent inhibitors of pseudomonal quorum sensing via pharmacophore modeling and In silico screening. Bioorg. Med. Chem. Lett. 16 (2006) 5902-5906
32. Moffat K., Gillet V.J., Whittle M., Bravi G., and Leach A.R. A comparison of field-based similarity searching methods, CatShape, FBSS, and ROCS. J. Chem. Inf. Model 48 (2008) 719-729
33. Durley R.C., Grapperhaus M.L., Massa M.A., Mischke D.A., Parnas B.L., Fobian Y.M., Rath N.P., Honda D.D., Zeng M., Connolly D.T., Heuvelman D.M., Witherbee B.J., Glenn K.C., Krul E.S., Smith M.E., and Sikorski J.A. Discovery of chiral N, N-disubstituted trifluoro-3-amino-2-propanols as potent inhibitors of cholesteryl ester transfer protein. J. Med. Chem. 43 (2000) 4575-4578
34. Massa M.A., Spangler D.P., Durley R.C., Hickory B.S., Connolly D.T., Witherbee B.J., Smith M.E., and Sikorski J.A. Novel heteroaryl replacements of aromatic 3-tetrafluoroethoxy substituents in trifluoro-3-(tertiary amino)-2-propanols as potent inhibitors of cholesteryl ester transfer protein. Bioorganic. Med. Chem. Lett. 11 (2001) 1625-1628
35. Durley R.C., Grapperhaus M.L., Hickory B.S., Massa M.A., Wang J.L., Spangler D.P., Mischke D.A., Parnas B.L., Fobian Y.M., Rath N.P., Honda D.D., Zeng M., Connolly D.T., Heuvelman D.M., Witherbee B.J., Melton M.A., Glenn K.C., Krul E.S., Smith M.E., and Sikorski J.A. Chiral N,N-disubstituted trifluoro-3-amino-2-propanols are potent inhibitors of cholesteryl ester transfer protein. J. Med. Chem. 45 (2002) 3891-3904
36. Reinhard E.J., Wang J.L., Durley R.C., Fobian Y.M., Grapperhaus M.L., Hickory B.S., Massa M.A., Norton M.B., Promo M.A., Tollefson M.B., Vernier W.F., Connolly D.T., Witherbee B.J., Melton M.A., Regina K.J., Smith M.E., and Sikorski J.A. Discovery of a simple picomolar inhibitor of cholesteryl ester transfer protein. J. Med. Chem. 46 (2003) 2152-2168
37. Sheridan R.P., and Kearsley S.K. Why do we need so many chemical similarity search methods?. Drug Discov. Today 7 (2002) 903-911
38. Fisher R. The Principle of Experimentation Illustrated by a Psycho-Physical ExpeHafner Publishing Co. eighth ed. (1966), Hafner Publishing, New York
39. Tropsha A., Gramatica P., and Gombar V.K. Quant. structure-activity relationship. Comb. Sci. 22 (2003) 69-77
40. CERIUS2 QSAR Users' Manual (2005), Accelrys Inc., San Diego, CA
41. Maguna F.P., Nunez M.B., Okulik N.B., and Castro E.A. Methodologies QSAR/QSPR/QSTR: current state and perspectives. Int. J. Chem. Model 1 2 (2009) 221-243
42. Ramsey L.F., and Schafer W.D. The Statistical Sleuth. first ed. (1997), Wadesworth Publishing Company, USA
43. Krovat E.M., and Langer T. Non-peptide angiotensin ii receptor antagonists: chemical feature based pharmacophore identification. J. Med. Chem. 46 (2003) 716-726
44. Kier L.B., and Hall L.H. In: Devillers J., and Balaban A.T. (Eds). Topological Indices and Related Descriptors in QSAR and QSPR (1999), Gordon and Breach, London 491-562
45. Homans S.W. Water, water everywhere - except where it matters? Drug Discov. Today 12 (2007) 534-539
46. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Del. Rev. 46 (2001) 3-26
47. Veber D.F., Johnson S.R., Cheng H.Y., Smith B.R., Ward K.W., and Kopple K.D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45 (2002) 2615-2623
48. Ivanov I., Nikolova S., and Statkova-Abeghe S. Efficient one-pot friedel-crafts acylation of benzene and its derivatives with unprotected aminocarboxylic acids in polyphosphoric acid. Synth. Commun. 36 (2006) 1405-1411
49. del Amo V., and Philp D. Making imines without making water-exploiting a recognition-mediated Aza-Wittig reaction. Org. Lett. 11 (2009) 301-304
50. Verdonk M.L., Marcel L., Berdini V., Hartshorn M.J., Mooij W.T.M., Murray C.W., Taylor R.D., and Watson P. Virtual screening using protein-ligand docking: avoiding artificial enrichment. J. Chem. Inf. Comput. Sci. 44 (2004) 793-806
51. Kirchmair J., Markt P., Distinto S., Wolber G., and Langer T. Evaluation of the performance of 3D virtual screening protocols: RMSD comparisons, enrichment assessments, and decoy selection-what can we learn from earlier mistakes?. J. Comput. Aided. Mol. Des. 22 (2008) 213-228
52. Irwin J.J., and Shoichet B.K. ZINC - a free database of commercially available compounds for virtual screening. J. Chem. Inf. Comput. Sci. 45 (2005) 177-182
53. Triballeau N., Acher F., Brabet I., Pin J.P., and Bertrand H.O. Virtual screening workflow development guided by the "receiver-operating characteristic" curve approach. application to high-throughput docking on metabotropic glutamate receptor subtype 4. J. Med. Chem. 48 (2005) 2534-2547
54. Jacobsson M., Liden P., Stjernschantz E., Bostroem H., and Norinder U. Improving structure-based virtual screening by multivariate analysis of scoring data. J. Med. Chem. 46 (2003) 5781-5789
55. Gao H., Williams C., Labute P., and Bajorath J. Binary quantitative structure-activity relationship (QSAR) analysis of estrogen receptor ligands. J. Chem. Inf. Comput. Sci. 39 (1999) 164-168
56. Hahn M. Three-dimensional shape-based searching of conformationally flexible compounds. J. Chem. Inf. Comput. Sci. 37 (1997) 80-86